6 stories mentioning SHE:300759Updated 14d ago
Every FINWIRES story that references SHE:300759, newest first.
Pharmaron Beijing (SHE:300759) has an average rating of overweight and mean price target of 36.79 yuan, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Pharmaron Beijing (SHE:300759) forecasts a 4% to 10% rise in its net attributable profit to between 729.5 million yuan and 771.5 million yuan in the first half from 701.4 million yuan in the year-ago period, according to a Tuesday filing with the Shenzhen bourse.The drug research company expects earnings per share to grow to between 0.4024 yuan and 0.4256 yuan from 0.3984 yuan in the year-ago period.Revenue is expected to rise 16% to 19% to between 7.47 billion yuan and 7.66 billion yuan from 6.44 billion yuan in the prior-year period.Pharmaron attributed the expected rise to an increase in new orders following the advancement of its small molecule CDMO service pipeline.
Hong Kong stocks closed higher Tuesday as stronger-than-expected Chinese trade data offset renewed concerns over escalating U.S.-Iran tensions and higher oil prices.The Hang Seng Index rose 0.5%, or 127.01 points, to close at 24,340.73, while the Hang Seng China Enterprises Index gained 0.5%, or 37.11 points, to finish at 8,103.08.China's June trade data exceeded expectations, pointing to resilient external demand. Exports rose 27% year over year, while imports climbed 36%, with both figures topping analysts' forecasts.The trade surplus widened to $125.6 billion from $105.4 billion in May, beating the consensus forecast.Meanwhile, oil prices climbed after U.S. President Donald Trump said Washington was reinstating its blockade of Iranian shipping and would impose a 20% fee on cargo transiting the Strait of Hormuz.In corporate news, Pharmaron Beijing (HKG:3759, SHE:300759) closed over 6% higher after forecasting up to a 10% rise in first-half profit.CNGR Advanced Material (HKG:2579, SHE:300919) advanced over 8% after flagging an 84% first-half profit jump.
Pharmaron Beijing (HKG:3759, SHE:300759) expects attributable net profit of 729.5 million yuan to 771.5 million yuan for the six months ended June 30, up 4% to 10% from 701.4 million yuan a year earlier, according to a Monday filing with the Hong Kong bourse.The pharmaceutical company expects first-half revenue of 7.47 billion yuan to 7.66 billion yuan, up 16% to 19% from 6.44 billion yuan in the prior-year period.Pharmaron attributed the expected growth to stronger strategic customer demand and robust growth in its small-molecule CDMO business, with newly signed orders rising more than 30% in the first half.
Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.
Pharmaron Beijing (HKG:3759, SHE:300759) recorded a 9.8% rise in attributable profit in the first quarter of 2026 to 335.4 million yuan from 305.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The pharmaceutical company's earnings per share rose to 0.185 yuan from 0.1733 yuan in the corresponding period of the previous fiscal year.Revenue jumped 15% to 3.58 billion yuan from 3.1 billion yuan in the year-ago period.
